Jean Jacques Bienaime - Jan 18, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Jan 18, 2024
Transactions value $
-$774,046
Form type
4
Date filed
2/12/2024, 05:20 PM
Previous filing
Jan 11, 2024
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Small acquisition under Rule 16a-6 $3.7K +40 +0.01% $92.60 420K Jan 18, 2024 Direct F1, F2
transaction BMRN Common Stock Options Exercise $947K +15K +3.57% $63.10 435K Feb 8, 2024 Direct F3
transaction BMRN Common Stock Sale -$1.35M -15K -3.45% $89.77 420K Feb 8, 2024 Direct F3
transaction BMRN Common Stock Options Exercise $947K +15K +3.57% $63.10 435K Feb 9, 2024 Direct F3
transaction BMRN Common Stock Sale -$1.32M -15K -3.45% $88.28 420K Feb 9, 2024 Direct F3
holding BMRN Common Stock 247K Jan 18, 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Jan 18, 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 Jan 18, 2024 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -15K -9.32% $0.00 146K Feb 8, 2024 Common Stock 15K $63.10 Direct F4
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -15K -10.27% $0.00 131K Feb 9, 2024 Common Stock 15K $63.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F2 The price in column 4 is the weighted average price. The purchase price actually paid ranged from $92.595 to $92.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.